Why did CVKD's EPS remain flat in recent quarters?

The EPS of CVKD has not shown significant variation in recent quarters, remaining largely flat, which can be attributed to several key factors: 1. **Revenue Focus on Product Development**: The company's focus on developing tecarfarin, a novel oral anticoagulant, has been a primary driver of its financials. The continued investment in this product candidate explains the sustained expenditure that has kept the EPS relatively flat. 2. **Increased General and Administrative Expenses**: CVKD has reported higher general and administrative expenses, primarily due to increased personnel-related expenses, public company costs, and stock-based compensation. These increases have been a significant factor in the higher operating expenses that have impacted the net loss, indirectly influencing the EPS. 3. **Research and Development Costs**: The company's research and development expenses have risen slightly, attributed to higher costs associated with chemistry, manufacturing, and controls, as well as consulting fees. These increases reflect the company's ongoing efforts to advance its product pipeline, which has helped to maintain a steady level of expenditure that has not significantly altered the EPS. 4. **Strategic Collaborations and Financing Activities**: CVKD has been active in strategic collaborations, such as the partnership with Abbott for the pivotal TECH-LVAD trial, which is expected to leverage Abbott's insights to aid in trial design and site identification. Additionally, the company has secured financing through share sales, which has bolstered its working capital for advancing tecarfarin and preparing for future clinical trials. In summary, CVKD's EPS has remained relatively flat due to a combination of factors, including a strong focus on product development, increased general and administrative expenses, rising research and development costs, and strategic collaborations and financing activities. These elements have collectively contributed to a stable financial outlook for the company despite the fluctuations in net loss and revenue.